Described by one delegate as “insightful with a good balance of deep scientific knowledge and impact”, the DDW Turning Science into Business Symposium, offered a focused afternoon on drug discovery science, technology, opportunity and success for the future.

This inaugural event attracted senior figures from pharma, biotech, investment and technology on 4 November. It was well received by the audience at The Francis Crick Institute, London, for its mix of high quality scientific presentations, deep dive into the drug discovery sector and focus on where improvements could be made to ensure future profitability.

“We received such positive comments about the content programme as well as the quality of attendees on the day. With so many events to choose from in the drug discovery space, the DDW team worked hard to ensure we had a strong mix of science and business on offer. We understand how precious time is for everyone working in this sector so it’s important to hit the right note and offer content that educates both scientifically as well as on a business level,” said Lu Rahman, Publishing Director.

“The level of interest shown by the audience post sessions and in the networking was highly encouraging and insightful,” added Reece Armstrong, DDW Editor. “It’s great to see the sector coming together to discuss their work and the future of drug discovery.” If you missed the event you can now view it on demand here.

The on-demand version of the DDW Turning Science into Business Symposium is only available for a limited time! Register now to watch before December 24th!

Speakers:

Dr Daniil Bash, Lead Scientist at the Innovation Centre in Digital Molecular Technologies (iDMT), University of Cambridge discussed AI-optimisation of flow-based small molecule organic synthesis.

Nikhil Gupta, Principal Scientist, Cancer Research Horizons – AstraZeneca Functional Genomics Centre, brought us Advancing Oncology Drug Discovery Through CRISPR Screening.

Lawrence Welch, Inside Sales Specialist, Nuclera described Unlocking drug targets: 48-Hour production of membrane proteins, E3 ligases, and transcription factors with eprotein discovery.

Chas Bountra, Pro-Vice-Chancellor for Innovation, Professor of Translational Medicine, Oxford University enlightened with Building an ecosystem to rival Boston or Stanford.

Dr Cathy Tralau-Stewart, Executive Director, The Milner Therapeutics Institute, University of Cambridge presented Connecting academic research with industry to drive therapeutic discoveries.

Professor Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK, Oxford Drug Discovery Institute delivered Innovations in target identification, validation and drug discovery for neurodegenerative diseases.

The panel provided a fascinating insight into Technology, market forces and new ways of working – the challenges facing drug discovery and how to overcome them involving Joanne Taylor, SVP Research, Gain Therapeutics, Nadine Clemo, VP Global Program Leader, Apollo Therapeutics, and Dr Cathy Tralau-Stewart, Executive Director, The Milner Therapeutics Institute, University of Cambridge.

The event was sponsored by Nuclera (lead sponsor), Collaborative Drug Discovery (coffee break sponsor) and Thermo Fisher Scientific. Register now to watch the recording.